A Phase 2a Randomized, Double-Blind, Multicenter, Placebo and Active Controlled Study to Assess Analgesic Efficacy and Safety of ASP3662 in Subjects With Painful Diabetic Peripheral Neuropathy
Latest Information Update: 01 Apr 2019
At a glance
- Drugs ASP 3662 (Primary) ; Pregabalin
- Indications Neuropathic pain
- Focus Therapeutic Use
- Sponsors Astellas Pharma
- 03 Jun 2016 Status changed from recruiting to discontinued.
- 18 Jun 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
- 03 Mar 2015 New trial record